Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.17
Views: 1246

Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Dr Schuster presents, in a press conference at the 2017 ASH annual meeting, data from the phase 2 JULIET trial looking at CTL019 (tisagenlecleucel) in adult patients with relapsed or refractory diffuse large B-Cell lymphoma.

Read the news story or watch our interview with Dr Schuster for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation